🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Carolyn Owen

University of Calgary

ORCID: 0000-0003-4110-1708

Also affiliated with Occupational Cancer Research Centre

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile
1.3Author DataRank

Indexed papers

3in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy

Haematologica(2021)10.3324/haematol.2021.278762
Top 16%
1.3DataRank
Top 16%55 citations

Sarah L. King‐Smith, David Lawrence, Peer Arts, Jinghua Feng, James Andrews +38 more

Papers

Driven by 12 papers — median percentile 84. Top paper: “Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study”.

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Journal of Clinical Oncology(2020)10.1200/jco.20.00948
N/A
4.9DataRank · unranked
223 citations

Jenny Wu, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, James D’Rozario +23 more

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Blood(2022)10.1182/blood.2021015014
N/A
3.8DataRank · unranked
153 citations

Thomas J. Kipps, Barbara Eichhorst, James D’Rozario, Carolyn Owen, Sarit Assouline +16 more

The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy

Haematologica(2021)10.3324/haematol.2021.278762
Top 16%
1.3DataRank
Top 16%55 citations

Sarah L. King‐Smith, David Lawrence, Peer Arts, Jinghua Feng, James Andrews +38 more

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

NEJM Evidence(2022)10.1056/evidoa2200006
N/A
0.818DataRank · unranked
233 citations

Carolyn Owen, Carol Moreno, George Follows, Talha Munir, Mark-David Levin +16 more

Germline variants drive myelodysplastic syndrome in young adults

Leukemia(2021)10.1038/s41375-021-01137-0
N/A
0.631DataRank · unranked
66 citations

Jane E. Churpek, Tom Walsh, Sioḃán Keel, Marja Hakkarainen, Thomas Schroeder +30 more

Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41

Blood Advances(2023)10.1182/bloodadvances.2023010045
N/A
0.557DataRank · unranked
40 citations

Michael W. Drazer, Kai Yu, David Lawrence, Jinghua Feng, Luis Arriola‐Martinez +60 more

Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia

Journal of Geriatric Oncology(2023)10.1016/j.jgo.2023.101538
N/A
0.457DataRank · unranked
20 citations

Jennifer A. Woyach, Angela K. Ulrich, Veronique Marcotte, Ryan David Nipp, Daniel E. Lage +17 more

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations

Blood(2025)10.1182/blood.2024028064
N/A
0.425DataRank · unranked
16 citations

Monia Marchetti, Othman Al‐Sawaf, Ohad Benjamini, Alexey V. Danilov, Matthew S. Davids +24 more

Underrepresentation of Small Lymphocytic Lymphoma in Clinical Trials for Chronic Lymphocytic Leukemia

European Journal of Haematology(2025)10.1111/ejh.14376
N/A
0.208DataRank · unranked
3 citations

Carolyn Owen, Anthea Peters, Robert Puckrin

A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia

Clinical Lymphoma Myeloma & Leukemia(2021)10.1016/j.clml.2021.06.011
N/A
0DataRank · unranked
5 citations

Nicole Mittmann, Carolyn Owen, Nizar Abdel‐Samad, Graeme Fraser, Selay Lam +15 more

Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry program

Discover Oncology(2025)10.1007/s12672-025-02433-2
N/A
0DataRank · unranked
0 citations

Maria Badikyan, Marina Konopleva, Alvaro J. Alencar, Arusyak Ivanyan, Carolyn Owen +34 more

Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e20004
N/A
0DataRank · unranked
0 citations

Sumithra J. Mandrekar, Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander +15 more